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Abstract Pre-exposure prophylaxis (PrEP) for HIV pre-
vention is a promising experimental approach currently
being tested globally. A number of PrEP trials are evalu-
ating the safety and effectiveness of PrEP in men who have
sex with men (MSM) and other populations at risk for HIV,
and results will be available from this ﬁrst generation of
efﬁcacy trials over the next few years. Here we review the
rationale for orally-administered antiretrovirals for pre-
vention, and outline issues the ﬁrst generation trials will
address as well as questions that may be addressed in future
studies. We also describe the rationale for combination
prevention approaches that may combine PrEP with other
prevention modalities as part of a larger prevention
package.
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Introduction
‘‘Can a pill a day prevent HIV?’’ That is the tagline of
recruitment advertisements for an HIV prevention trial to
test whether a combination pill (tenofovir/emtricitabine or
Truvada
) can reduce the number of HIV infections when
taken daily by men who have sex with men (MSM). This
approach, also known as pre-exposure prophylaxis (PrEP),
is being evaluated in a number of studies in different
populations worldwide, using either a daily tenofovir or
Truvada
 pill. Early data from PrEP trials were presented
at the International AIDS Society conference in Vienna in
July 2010 [1–3]; additional results are likely to be pre-
sented and/or published prior to this article appearing in
print. Tenofovir gel is also being evaluated as ‘‘topical
PrEP’’ (also known as microbicides) vaginally and rectally,
and is more fully described in the article by McGowan in
this issue of AIDS and Behavior.
In this article, we will review the rationale for using
orally-administered antiretrovirals for prevention in HIV
negative persons, both as post-exposure prophylaxis (PEP)
and pre-exposure prophylaxis (PrEP). We will outline the
issues the ﬁrst generation of trials are designed to address
as well as questions that must be addressed by future
studies. Because pills alone will never completely control
the AIDS epidemic, we will also discuss the rationale for
combination prevention approaches that may combine
PrEP (if proven efﬁcacious) with other prevention
strategies.
Rationale for HIV Prophylaxis Using Antiretroviral
Agents
A number of infectious diseases can be prevented by
administering antimicrobials to persons at high-risk of
acquiring the disease prior to and during periods of expo-
sure. For example, persons traveling in regions of the world
with high rates of malaria take anti-malarial agents to
prevent infection [4]. Antiretroviral agents have greatly
reduced HIV transmission to newborns when provided to
HIV-positive mothers at the time of delivery [5].
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to prevent HIV infection came from studies in the early
1990’s of zidovudine prophylaxis in mice [6] and non-
human primates [7]. These and later studies demonstrated
that antiretrovirals were most efﬁcacious if given prior to
or within hours after HIV or SIV challenge, and continued
for 4 weeks. Tsai [8] later demonstrated the improved
efﬁcacy of PMPA (tenofovir) over zidovudine in protecting
adult macaques against intravenous SIV challenge. More
recent studies have demonstrated the efﬁcacy of tenofovir
or Truvada
 in preventing infections when animals are
challenged rectally with SIV [9].
These studies, in fact, served as a proof of principle for
post-exposure prophylaxis (PEP), that is, administering
antiretroviral agents within hours after an HIV exposure,
and continuing treatment for 4 weeks. Although no ran-
domized controlled trial of PEP has been conducted in
humans, an observational case–control study in health care
workers with occupational exposures demonstrated a sig-
niﬁcantlylower rateofHIVinfection amongthose whotook
AZT compared to those who did not [10], leading to the US
Centers for Disease Control and Prevention’s recommen-
dations for PEP for occupational exposures [11], and
eventually for high-risk non-occupational exposures [12].
Animal data suggest that for PEP to be effective, per-
sons at risk would have to recognize they had been
potentially exposed to HIV and initiate treatment within
hours of exposure, making PEP an unlikely strategy for
reducing HIV incidence in populations with repeated high-
risk exposures. In fact, a number of PEP failures occurred
in MSM who were given antiretrovirals to keep at home,
but who did not initiate PEP because they did not recognize
exposures as high risk [13]. A prospective study of high-
risk uninfected MSM from six US cities found that only a
small fraction had single exposures to HIV prior to their
infection; almost all had repeated exposures, and few rec-
ognized the frequency of exposures [14]. This would sug-
gest that, to be effective, antiretroviral agents might need to
be administered throughout periods of risk, the rationale
behind PrEP.
PrEP Trial Overview
The ﬁrst generation of PrEP trials are projected to enroll a
diverse population of more than 20,000 men and women in
Africa, the Americas, and Asia (Table 1). Three PrEP
studies to date have focused on MSM populations: a safety
study of daily oral tenofovir in US MSM; an efﬁcacy study
of oral daily Truvada
 in MSM in Peru, Ecuador, Brazil,
the US, South Africa, and Thailand; and a study of PrEP
safety, feasibility, and acceptability in young MSM. Other
PrEP trials are exploring the safety and efﬁcacy of
tenofovir-based regimens in injection drug users (IDU),
heterosexual men and women, or heterosexual couples. A
website with frequently updated information about clinical
PrEP trials is hosted by the AIDS Vaccine Advocacy
Coalition: http://www.prepwatch.org.
Tenofovir-based regimens were chosen on the strength
of pre-clinical trials, as well as the excellent safety, toler-
ability, and resistance proﬁles of these regimens when used
for HIV treatment. Each of these trials will provide sub-
stantial tolerability and safety data in these diverse popu-
lations. Some trials are conducting sub-studies to assess
speciﬁc safety concerns, such as additional laboratory
assays to evaluate potential renal toxicity, or dual energy
X-ray absorptiometry (DEXA) to evaluate the effect of
tenofovir-based regimens on bone mineral density and
body composition.
All studies will measure pill-taking practices through
participant self-report; many studies will augment these
studies through objective measures (e.g., counting returned
pills, microchips that record opening of pill bottles, drug
levels in plasma, blood cells, and/or hair). There is, as yet,
no ‘‘gold standard’’ for measuring true pill-taking practices,
but these studies will evaluate the correlation between
various measures of pill adherence, and ultimately, whether
any of these measures is highly correlated with PrEP
efﬁcacy.
All studies are also assessing sexual and drug-use
practices during the course of the trial. Concern has been
raised that persons may increase their risk practices if they
have access to effective prevention strategies; this change
in risk behavior may be due to a reduction in self-imposed
limits to avoid risk (behavioral disinhibition) or decreasing
perception of risk (risk compensation) with the availability
of the new prevention tool [15, 16]. The CDC-sponsored
US trial of oral daily tenofovir in MSM will directly assess
the potential for a change in sexual risk practices through
its unique study design: half of the participants are ran-
domized to take a daily pill (tenofovir or placebo) upon
enrollment, while the other half are randomly assigned to
wait 9 months before starting their daily study pill (Fig. 1).
This allows a direct comparison of risk practices while men
are or are not taking a daily pill, and may provide an early
indication if there is likely to be substantial risk compen-
sation. However, because participants in this trial know the
efﬁcacy of PrEP is not yet proven, and that they may be
receiving placebo, this measure may under-estimate risk
compensation that could occur if PrEP is found to be
efﬁcacious, and if persons are to take PrEP outside the
context of a placebo-controlled trial.
Most of these studies are also powered to evaluate PrEP
efﬁcacy. Most are evaluating a single daily oral regimen,
although the Partners in Prevention trial will evaluate both
daily oral tenofovir versus Truvada
, and the VOICE trial
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123will evaluate daily tenofovir, Truvada
, and daily vaginal
tenofovir. While neither of these multi-arm trials is pow-
ered for a direct head-to-head comparison of regimens,
both will provide comparative efﬁcacy data within the
same trial. These studies will also provide preliminary data
on impact on HIV viral load setpoint, CD4 cell counts, and
patterns of HIV resistance among seroconverters who
become infected while taking PrEP.
Lessons Learned and Future Directions
Adherence is Critical
Optimizing adherence and its measurement in prevention
clinical trials is critical for trial outcomes and interpreta-
tion. The CAPRISA 004 study of tenofovir vaginal gel
provided an important proof of concept that antiretroviral
agents can prevent HIV acquisition [3]. However, the trial
also demonstrated the importance of adherence in ultimate
PrEP effectiveness: self-reported high adherers ([80%
adherence as measured by returned gel applicators) had a
signiﬁcant protective effect (54% effectiveness, 95% con-
ﬁdence interval (CI) 4–80%), while low adherers (\50%
adherence) had no signiﬁcant protection (28% effective-
ness, 95% CI 40–64%). Data from the iPrEx trial of oral
daily Truvada
 in MSM is not yet available at the time of
this writing. However, analyses are planned to evaluate the
effect of adherence (as measured both by self-report and
drug levels) on PrEP efﬁcacy.
One challenge to interpreting efﬁcacy results is the
veracity of self-reported measures, where over-reporting
may commonly occur. In the Carraguard vaginal microbi-
cide trial, for instance, adherence to prescribed microbicide
use was 96% via self-report but only 42% on the basis of
applicator testing [17]. Data from a sub-study of the US-
based MSM safety trial found relatively poor correlation
between various adherence and drug exposure measures
[18]. Many factors may be responsible for these
discrepancies, including misunderstanding of study ques-
tions, memory lapses, social desirability bias, or differ-
ences in drug absorption, metabolism, or penetration into
various tissues. Adherence and drug exposure measures
will be most useful if they can reproducibly deﬁne patterns
or thresholds of pill-taking required for maximum effec-
tiveness, and point to mechanisms by which effectiveness
may be impaired. Strategies to promote pill use in PrEP
trials and to facilitate accurate reporting of product use are
currently being explored [19].
Only limited data to date have been presented on
adherence patterns in oral PrEP trials. Preliminary analysis
from a comparison of daily versus ﬁxed plus post-coital
dosing in Kenya and Uganda suggested that adherence to
daily and ﬁxed-dose regimens were relatively high and
better than post-coital dosing, although accurate measure-
ment of post-coital pill use may have been an issue [2]. It is
not yet known what schedule of PrEP dosing will be most
effective, nor what level of adherence will be required for
maximum tolerability and efﬁcacy.
Importance of Community Engagement in All Stages
of Research
Early planned PrEP trials (efﬁcacy trials in Cambodia,
Cameroon, Malawi, and three West African sites) were not
launched or were stopped prematurely because of ethical,
political, and logistical issues raised by community mem-
bers, advocates, government ofﬁcials, and clinical trial
sponsors [20]. Difﬁcult as these situations were for all
parties involved, the resulting discussions that arose as a
result of these challenges strengthened the next generation
of trials, which included full involvement of community
members, support of government ofﬁcials, and strong
oversight of clinical study operations. Community con-
sultation must start early and involve multiple community
groups, which may have distinct perspectives and interests.
These engagement efforts should promote communication
between researchers and community as well as among
different community groups through transparent discus-
sions [21]. UNAIDS has recently issued a revised version
of good participatory practice (GPP) for biomedical HIV
prevention trials [22]; this document highlights the
importance of stakeholder engagement at each stage of the
research life-cycle.
Attention to Trial Planning and Conduct is Paramount
In addition to the importance of community engagement,
the successful conduct of PrEP research requires great
attention to the mechanics of clinical trial implementation.
PrEP trials are highly complex, and successful conduct of
PrEP trials depends on talented investigators with access to
Fig. 1 Study design of US CDC tenofovir (TDF) study
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123appropriate populations to achieve rapid accrual rates,
adequate seroincidence in the context of best prevention
strategies, and adherence to protocol requirements. PrEP
clinical trials have faced numerous challenges on these
fronts. For example, the US PrEP trial among MSM
experienced slower than projected enrollment; important
lessons learned included the importance of centrally coor-
dinated recruitment strategies and campaigns, and the need
for streamlined regulatory approvals and support for
innovative strategies, including use of the Internet [23].
Lower seroincidence was observed in both the West Afri-
can PrEP study [24] and CDC Botswana trial [25], but may
have been due to overall secular trends in the community,
inaccurate pre-trial estimates of HIV incidence, and
intensive prevention services provided in the trial. Adher-
ence to protocol requirements is also critical. Missed visits
and pregnancy were primary reasons for time off study
drug in the West African PrEP study. Low retention in the
CDC Botswana PrEP study contributed to the premature
closure of that trial. Ideally, plans to achieve rapid
enrollment, adequate HIV seroincidence, and excellent
retention rates in trials should begin prior to study launch,
and adequate resources should be in place to address
difﬁculties.
Many Questions Will Remain After the First Round
of PrEP Studies
Even if all of the ﬁrst and second generation PrEP studies
are conducted with excellent adherence to study proce-
dures, many questions will remain after results are avail-
able (Table 2). Data to date suggest that oral tenofovir is
relatively well-tolerated in HIV-negative individuals, with
no substantial safety concerns after up to 12 months of use
in women in West Africa [24] and up to 24 months in
MSM in the US [1]. However, only preliminary safety
analyses were presented on the US MSM safety trial;
additional analyses, including studies of the effect of daily
tenofovir or Truvada
 on bone mineral density have not
yet been completed. In addition, safety data have not yet
been reported for other populations, including IDU and
youth, and are not collected comprehensively in pregnant
or lactating women, or in persons with underlying medical
conditions. Also, the long-term safety of ongoing use of
antiretrovirals for prevention is unknown.
All PrEP efﬁcacy studies will measure drug resistance in
breakthrough infections. However, numbers of infections
on PrEP may be small, and pooling data across PrEP
studies will help identify resistance issues. All current
studies focus on tenofovir-based regimens; there is interest
in developing other antiretroviral agents for PrEP to
improve on the safety and/or efﬁcacy proﬁle, or to reduce
the possibility of drug resistance.
Some of the most substantive questions will need to be
addressed if PrEP is found to be efﬁcacious in clinical
trials. Modeling exercises suggest that PrEP could sub-
stantially reduce new infections at a population level, but
that efﬁcacy could suffer if risk practices also increase [26,
27]. If PrEP is found to be efﬁcacious, additional studies to
measure the effect of knowledge of PrEP efﬁcacy on risk
behavior and adherence will be needed. PrEP impact may
be highest if delivered to those at highest risk of acquiring
HIV. Several studies have surveyed MSM about their
interest in taking PrEP if found to be efﬁcacious, and these
suggest that men with substantial risk may be willing to
take PrEP [28–30]. However, whether and how these men
might use PrEP is not yet known. Substantial work is
required to determine how best to deliver PrEP to various
populations in various settings [31]. PrEP delivery will
require coordination of different PrEP delivery compo-
nents, including outreach, screening, drug prescribing and
delivery, HIV and additional safety testing, and interven-
tions to sustain pill use and behavioral risk reduction over
the long term [32]. In addition to consideration of various
political, legal, and cultural issues, questions remain about
the frequency and intensity of clinical monitoring and HIV
testing, how best to identify and engage high-risk popula-
tions, methods of reimbursement, and the types of clinical
or community-based facilities that may be best equipped to
deliver PrEP in various settings.
Combination Prevention Strategies
No infectious disease has been eliminated through anti-
microbials alone; control of the HIV epidemic is most
likely to come through a combination of biomedical and
behavioral interventions [33]. For example, the 50%
reduction in mortality from coronary heart disease from
1980 to 2000 in the US was achieved through a relatively
equal contribution of modiﬁcation of risk factors (e.g.,
decreasing prevalence of smoking) and biomedical inter-
ventions (e.g., interventional and pharmacologic therapies)
[34]. Understanding the factors leading to epidemic spread,
as reported in Anderson and May’s classic article [35],
suggests that combination interventions that target different
mechanisms of an epidemic may be synergistic at a pop-
ulation level. For example, Hallett modeled the impact of
combining widespread male circumcision with a behavior
change program in South Africa [36]. In this model,
widespread male circumcision (90% coverage) alone
would lead to an approximate 1/3 reduction in HIV inci-
dence at a population level; a behavior change program
with a 30% reduction in partner change rate and 30%
increase in condom use would lead to an approximate 2/3
reduction in HIV incidence rates. However, if male
S76 AIDS Behav (2011) 15:S72–S79
123circumcision were combined with a behavior change pro-
gram, HIV incidence would be virtually eliminated.
Similar to topically-applied PrEP, which was recently
shown to be 39% effective in reducing HIV infections in
African women [3], oral PrEP is unlikely to be 100%
effective. PrEP would therefore need to be combined with
other prevention interventions to have the biggest impact.
Other articles in this issue of AIDS and Behavior review
other types of interventions that may be useful for con-
trolling the HIV epidemic in MSM, and if efﬁcacious, may
be combined with PrEP to increase the protective effect. In
particular, it will be important to test interventions that
could be coupled with PrEP to minimize risk compensation
and maximize adherence in the setting of known efﬁcacy
and implementation outside of clinical trials. Other
behavioral interventions, treatment of substance abuse,
rectal microbicides, increased HIV testing and disclosure,
and programs to promote the sexual health and overall
well-being of MSM may all play an important role in
control of the HIV epidemic in MSM. Combination pre-
vention interventions will need to be feasible to deliver and
attractive to diverse MSM populations. The Prevention
Umbrella for MSM in the Americas (PUMA) is an R01-
funded planning project to evaluate how best to combine
and deliver a package of interventions to have the biggest
impact on driving down HIV infection rates in MSM.
The next few years will tell us whether PrEP can be
efﬁcacious and deliverable in diverse populations of MSM
worldwide. Future efforts will focus on maximizing the
effectiveness and cost-effectiveness of PrEP, and
Table 2 Data available from current PrEP trials, and areas for future studies
Data provided by current trials Gaps to be addressed in future trials
Biological safety (frequency
of adverse events, including
renal, hepatic, bone,
and metabolic toxicities)
Clinical safety of daily oral TDF in MSM, IDU Safety of longer term use ([several years) in all
populations
Safety of FTC/TDF in MSM, heterosexual men and
women and serodiscordant couples in Africa
Safety of use in pregnancy or breastfeeding
Safety of intermittent FTC/TDF in serodiscordant
couples and men and women in Africa
Safety in persons with chronic disease (renal,
hepatic)
Safety of daily vaginal tenofovir gel in African
women
Optimal frequency of safety monitoring
Safety of other medications for PrEP
Safety of topical tenofovir gel for rectal use
Efﬁcacy Efﬁcacy of daily oral FTC/TDF in MSM,
heterosexual men and women in Africa, and
serodiscordant couples
Comparative efﬁcacy of intermittent PrEP versus
daily PrEP
Efﬁcacy of daily oral TDF in IDU Efﬁcacy of other medications for PrEP and other
routes of administration
Efﬁcacy of daily vaginal tenofovir gel Mechanisms for differences (if found) in efﬁcacy
results between different trials
Efﬁcacy for different routes of exposure, including
anal/penile (MSM), penile/vaginal (heterosexual
men and women), and parenteral (IDU)
Effect on HIV viral load set point and CD4 among
seroconverters
Validation of non-human primate models of PrEP
efﬁcacy
Adherence Rates of pill or gel use based on multiple adherence
measures within a clinical trial
Pill or gel use rates when efﬁcacy of PrEP is known
and PrEP is taken outside of a clinical trial context
Correlation between different adherence and drug
exposure measures
Reproducible, easily obtained measures of drug
exposure that can be used in clinical practice
Behavior Effect of pill-taking on risk behavior in multiple
populations participating in double-blind, placebo-
controlled studies
Effect of pill-taking on risk behavior when efﬁcacy
is known and PrEP is provided outside of a clinical
trial context
Resistance Preliminary data on resistance patterns seen in
seroconverters
Rates of drug resistance with expanded PrEP use in
the community
Optimal frequency of HIV testing to minimize
resistance but increase feasibility of PrEP delivery
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123combining PrEP with behavioral and biomedical inter-
ventions to drive down HIV incidence in MSM and other
populations at risk for HIV.
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